Wulf, Gerald G.

[["dc.bibliographiccitation.journal","Frontiers in Immunology"],["dc.bibliographiccitation.volume","12"],["dc.contributor.affiliation","Tsamadou, Chrysanthi; \r\n1\r\nInstitute of Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service, Baden Wuerttemberg – Hessen, and University Hospital Ulm, Ulm, Germany"],["dc.contributor.affiliation","Engelhardt, Daphne; \r\n2\r\nInstitute of Transfusion Medicine, University of Ulm, Ulm, Germany"],["dc.contributor.affiliation","Platzbecker, Uwe; \r\n4\r\nDepartment of Hematology/Oncology, University of Leipzig, Leipzig, Germany"],["dc.contributor.affiliation","Sala, Elisa; \r\n5\r\nDepartment of Internal Medicine III, University of Ulm, Ulm, Germany"],["dc.contributor.affiliation","Valerius, Thomas; \r\n6\r\nSection for Stem Cell Transplantation and Immunotherapy, Department of Medicine II, Christian Albrechts University, Kiel, Germany"],["dc.contributor.affiliation","Wagner-Drouet, Eva; \r\n7\r\nDepartment of Medicine III, Johannes Gutenberg-University, Mainz, Germany"],["dc.contributor.affiliation","Wulf, Gerald; \r\n8\r\nDepartment of Hematology/Oncology, Georg-August-University, Göttingen, Germany"],["dc.contributor.affiliation","Kröger, Nicolaus; \r\n9\r\nDepartment of Stem Cell Transplantation, University Hospital Hamburg Eppendorf, Hamburg, Germany"],["dc.contributor.affiliation","Murawski, Niels; \r\n10\r\nDepartment of Internal Medicine I, Universitätsklinikum des Saarlandes, Homburg, Germany"],["dc.contributor.affiliation","Einsele, Hermann; \r\n11\r\nDepartment of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany"],["dc.contributor.affiliation","Schaefer-Eckart, Kerstin; \r\n12\r\nMedical Clinic 5: Hematology, Oncology, Nuremberg Hospital, Nuremberg, Germany"],["dc.contributor.affiliation","Freitag, Sebastian; \r\n13\r\nDepartment of Medicine III, Hematology/Oncology/Palliative Care, Rostock University Medical Center, Rostock, Germany"],["dc.contributor.affiliation","Casper, Jochen; \r\n14\r\nDepartment of Oncology and Hematology, Klinikum Oldenburg, University Clinic, Oldenburg, Germany"],["dc.contributor.affiliation","Kaufmann, Martin; \r\n15\r\n2nd Department of Internal Medicine, Oncology and Hematology, Robert Bosch Hospital, Stuttgart, Germany"],["dc.contributor.affiliation","Dürholt, Mareike; \r\n16\r\nHematology/Oncology, Evangelic Clinic Essen-Werden, Essen-Werden, Germany"],["dc.contributor.affiliation","Hertenstein, Bernd; \r\n17\r\nHematology/Oncology, Klinikum Bremen-Mitte, Bremen, Germany"],["dc.contributor.affiliation","Klein, Stefan; \r\n18\r\nUniversitätsmedizin Mannheim, Med. Klinik III, Mannheim, Germany"],["dc.contributor.affiliation","Ringhoffer, Mark; \r\n19\r\nMedizinische Klinik III, Städtisches Klinikum Karlsruhe, Karlsruhe, Germany"],["dc.contributor.affiliation","Frank, Sandra; \r\n20\r\nDRST –Deutsches Register für Stammzelltransplantationen, German Registry for Stem Cell Transplantation, Ulm, Germany"],["dc.contributor.affiliation","Neuchel, Christine; \r\n1\r\nInstitute of Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service, Baden Wuerttemberg – Hessen, and University Hospital Ulm, Ulm, Germany"],["dc.contributor.affiliation","Schrezenmeier, Hubert; \r\n1\r\nInstitute of Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service, Baden Wuerttemberg – Hessen, and University Hospital Ulm, Ulm, Germany"],["dc.contributor.affiliation","Mytilineos, Joannis; \r\n20\r\nDRST –Deutsches Register für Stammzelltransplantationen, German Registry for Stem Cell Transplantation, Ulm, Germany"],["dc.contributor.affiliation","Fuerst, Daniel; \r\n1\r\nInstitute of Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service, Baden Wuerttemberg – Hessen, and University Hospital Ulm, Ulm, Germany"],["dc.contributor.author","Tsamadou, Chrysanthi"],["dc.contributor.author","Engelhardt, Daphne"],["dc.contributor.author","Platzbecker, Uwe"],["dc.contributor.author","Sala, Elisa"],["dc.contributor.author","Valerius, Thomas"],["dc.contributor.author","Wagner-Drouet, Eva"],["dc.contributor.author","Wulf, Gerald"],["dc.contributor.author","Kröger, Nicolaus"],["dc.contributor.author","Murawski, Niels"],["dc.contributor.author","Einsele, Hermann"],["dc.contributor.author","Fuerst, Daniel"],["dc.contributor.author","Schaefer-Eckart, Kerstin"],["dc.contributor.author","Freitag, Sebastian"],["dc.contributor.author","Casper, Jochen"],["dc.contributor.author","Kaufmann, Martin"],["dc.contributor.author","Dürholt, Mareike"],["dc.contributor.author","Hertenstein, Bernd"],["dc.contributor.author","Klein, Stefan"],["dc.contributor.author","Ringhoffer, Mark"],["dc.contributor.author","Frank, Sandra"],["dc.contributor.author","Neuchel, Christine"],["dc.contributor.author","Schrezenmeier, Hubert"],["dc.contributor.author","Mytilineos, Joannis"],["dc.date.accessioned","2022-02-01T10:31:39Z"],["dc.date.available","2022-02-01T10:31:39Z"],["dc.date.issued","2021"],["dc.date.updated","2022-02-09T13:20:17Z"],["dc.description.abstract","The HLA-DRB3/4/5 loci are closely linked to the HLA-DRB1 gene. Mismatches in these loci occur with a frequency of about 8%–12% in otherwise 10/10 HLA-matched transplant pairs. There is preliminary evidence that these disparities may associate with increased acute graft-versus-host disease (GvHD) rates. The aim of this study was to analyze a large cohort of German patients and their donors for HLA-DRB3/4/5 compatibility and to correlate the HLA-DRB3/4/5 matching status with the outcome of unrelated hematopoietic stem cell transplantation (uHSCT). To this end, 3,410 patients and their respective donors were HLA-DRB3/4/5 and HLA-DPB1 typed by amplicon-based next-generation sequencing (NGS). All patients included received their first allogeneic transplant for malignant hematologic diseases between 2000 and 2014. Mismatches in the antigen recognition domain (ARD) of HLA-DRB3/4/5 genes were correlated with clinical outcome. HLA-DRB3/4/5 incompatibility was seen in 12.5% (n = 296) and 17.8% (n = 185) of the 10/10 and 9/10 HLA-matched cases, respectively. HLA-DRB3/4/5 mismatches in the ARD associated with a worse overall survival (OS), as shown in univariate (5-year OS: 46.1% vs. 39.8%, log-rank p = 0.038) and multivariate analyses [hazard ratio (HR) 1.25, 95% CI 1.02–1.54, p = 0.034] in the otherwise 10/10 HLA-matched subgroup. The worse outcome was mainly driven by a significantly higher non-relapse mortality (HR 1.35, 95% CI 1.05–1.73, p = 0.017). In the 9/10 HLA-matched cases, the effect was not statistically significant. Our study results suggest that mismatches within the ARD of HLA-DRB3/4/5 genes significantly impact the outcome of otherwise fully matched uHSCT and support their consideration upon donor selection in the future."],["dc.description.abstract","The HLA-DRB3/4/5 loci are closely linked to the HLA-DRB1 gene. Mismatches in these loci occur with a frequency of about 8%–12% in otherwise 10/10 HLA-matched transplant pairs. There is preliminary evidence that these disparities may associate with increased acute graft-versus-host disease (GvHD) rates. The aim of this study was to analyze a large cohort of German patients and their donors for HLA-DRB3/4/5 compatibility and to correlate the HLA-DRB3/4/5 matching status with the outcome of unrelated hematopoietic stem cell transplantation (uHSCT). To this end, 3,410 patients and their respective donors were HLA-DRB3/4/5 and HLA-DPB1 typed by amplicon-based next-generation sequencing (NGS). All patients included received their first allogeneic transplant for malignant hematologic diseases between 2000 and 2014. Mismatches in the antigen recognition domain (ARD) of HLA-DRB3/4/5 genes were correlated with clinical outcome. HLA-DRB3/4/5 incompatibility was seen in 12.5% (n = 296) and 17.8% (n = 185) of the 10/10 and 9/10 HLA-matched cases, respectively. HLA-DRB3/4/5 mismatches in the ARD associated with a worse overall survival (OS), as shown in univariate (5-year OS: 46.1% vs. 39.8%, log-rank p = 0.038) and multivariate analyses [hazard ratio (HR) 1.25, 95% CI 1.02–1.54, p = 0.034] in the otherwise 10/10 HLA-matched subgroup. The worse outcome was mainly driven by a significantly higher non-relapse mortality (HR 1.35, 95% CI 1.05–1.73, p = 0.017). In the 9/10 HLA-matched cases, the effect was not statistically significant. Our study results suggest that mismatches within the ARD of HLA-DRB3/4/5 genes significantly impact the outcome of otherwise fully matched uHSCT and support their consideration upon donor selection in the future."],["dc.description.sponsorship","Wilhelm Sander-Stiftung"],["dc.identifier.doi","10.3389/fimmu.2021.771449"],["dc.identifier.eissn","1664-3224"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/98915"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-517"],["dc.publisher","Frontiers Media S.A."],["dc.relation.eissn","1664-3224"],["dc.rights","http://creativecommons.org/licenses/by/4.0/"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0/"],["dc.title","HLA-DRB3/4/5 Matching Improves Outcome of Unrelated Hematopoietic Stem Cell Transplantation"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1931"],["dc.bibliographiccitation.issue","12"],["dc.bibliographiccitation.journal","Annals of Hematology"],["dc.bibliographiccitation.lastpage","1942"],["dc.bibliographiccitation.volume","95"],["dc.contributor.author","Schlenk, Richard F."],["dc.contributor.author","Luebbert, Michael"],["dc.contributor.author","Benner, Axel"],["dc.contributor.author","Lamparter, Alexander"],["dc.contributor.author","Krauter, Juergen"],["dc.contributor.author","Herr, Wolfgang"],["dc.contributor.author","Martin, Hans"],["dc.contributor.author","Salih, Helmut R."],["dc.contributor.author","Kuendgen, Andrea"],["dc.contributor.author","Horst, Heinz-August"],["dc.contributor.author","Brossart, Peter"],["dc.contributor.author","Goetze, Katharina S."],["dc.contributor.author","Nachbaur, David"],["dc.contributor.author","Wattad, Mohammed"],["dc.contributor.author","Koehne, Claus-Henning"],["dc.contributor.author","Fiedler, Walter"],["dc.contributor.author","Bentz, Martin"],["dc.contributor.author","Wulf, Gerald"],["dc.contributor.author","Held, Gerhard"],["dc.contributor.author","Hertenstein, Bernd"],["dc.contributor.author","Salwender, Hans"],["dc.contributor.author","Gaidzik, Verena I."],["dc.contributor.author","Schlegelberger, Brigitte"],["dc.contributor.author","Weber, Daniela"],["dc.contributor.author","Doehner, Konstanze"],["dc.contributor.author","Ganser, Arnold"],["dc.contributor.author","Doehner, Hartmut"],["dc.date.accessioned","2018-11-07T10:05:31Z"],["dc.date.available","2018-11-07T10:05:31Z"],["dc.date.issued","2016"],["dc.description.abstract","The aim of this clinical trial was to evaluate the impact of all-trans retinoic acid (ATRA) in combination with chemotherapy and to assess the NPM1 status as biomarker for ATRA therapy in younger adult patients (18-60 years) with acute myeloid leukemia (AML). Patients were randomized for intensive chemotherapy with or without open-label ATRA (45 mg/m(2), days 6-8; 15 mg/m(2), days 9-21). Two cycles of induction therapy were followed by risk-adapted consolidation with high-dose cytarabine or allogeneic hematopoietic cell transplantation. Due to the open label character of the study, analysis was performed on an intention-to-treat (ITT) and a per-protocol (PP) basis. One thousand one hundred patients were randomized (556, STANDARD; 544, ATRA) with 38 patients treated vice versa. Median follow-up for survival was 5.2 years. ITT analyses revealed no difference between ATRA and STANDARD for the total cohort and for the subset of NPM1-mutated AML with respect to event-free (EFS; p = 0.93, p = 0.17) and overall survival (OS; p = 0.24 and p = 0.32, respectively). Pre-specified PP analyses revealed better EFS in NPM1-mutated AML (p = 0.05) and better OS in the total cohort (p = 0.03). Explorative subgroup analyses on an ITT basis revealed better OS (p = 0.05) in ATRA for genetic low-risk patients according to ELN recommendations. The clinical trial is registered at clinicaltrialsregister.eu (EudraCT Number: 2004-004321-95)."],["dc.identifier.doi","10.1007/s00277-016-2810-z"],["dc.identifier.isi","000387354000001"],["dc.identifier.pmid","27696203"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/14163"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/38910"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","1432-0584"],["dc.relation.issn","0939-5555"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","All-trans retinoic acid as adjunct to intensive treatment in younger adult patients with acute myeloid leukemia: results of the randomized AMLSG 07-04 study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Frontiers in Immunology"],["dc.bibliographiccitation.volume","11"],["dc.contributor.affiliation","Mytilineos, Daphne; \r\n1\r\nInstitute of Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service, Baden Wuerttemberg-Hessen, and University Hospital Ulm, Ulm, Germany"],["dc.contributor.affiliation","Tsamadou, Chrysanthi; \r\n1\r\nInstitute of Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service, Baden Wuerttemberg-Hessen, and University Hospital Ulm, Ulm, Germany"],["dc.contributor.affiliation","Neuchel, Christine; \r\n1\r\nInstitute of Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service, Baden Wuerttemberg-Hessen, and University Hospital Ulm, Ulm, Germany"],["dc.contributor.affiliation","Platzbecker, Uwe; \r\n4\r\nDepartment of Hematology/Oncology, University of Leipzig, Leipzig, Germany"],["dc.contributor.affiliation","Bunjes, Donald; \r\n5\r\nDepartment of Internal Medicine III, University of Ulm, Ulm, Germany"],["dc.contributor.affiliation","Schub, Natalie; \r\n6\r\nDivision of Stem Cell Transplantation and Immunotherapy, 2nd Department of Medicine, University of Kiel, Kiel, Germany"],["dc.contributor.affiliation","Wagner-Drouet, Eva; \r\n7\r\nDepartment of Medicine III, Johannes Gutenberg-University Mainz, Mainz, Germany"],["dc.contributor.affiliation","Wulf, Gerald; \r\n8\r\nDepartment of Hematology/Oncology, Georg-August-University Göttingen, Göttingen, Germany"],["dc.contributor.affiliation","Kröger, Nicolaus; \r\n9\r\nDepartment of Stem Cell Transplantation, University Hospital Hamburg Eppendorf, Hamburg, Germany"],["dc.contributor.affiliation","Murawski, Niels; \r\n10\r\nDepartment Internal Medicine I, Universitätsklinikum des Saarlandes, Homburg, Germany"],["dc.contributor.affiliation","Einsele, Hermann; \r\n11\r\nDepartment of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany"],["dc.contributor.affiliation","Schaefer-Eckart, Kerstin; \r\n12\r\nMedizinische Klinik 5, Klinikum Nürnberg, Paracelsus Medizinische Privatuniversität, Nürnberg, Germany"],["dc.contributor.affiliation","Freitag, Sebastian; \r\n13\r\nDepartment of Medicine III, Hematology/Oncology/Palliative Care, Rostock University Medical Center, Rostock, Germany"],["dc.contributor.affiliation","Casper, Jochen; \r\n14\r\nDivision of Hematology and Oncology, Oldenburg Clinic, University of Oldenburg, Oldenburg, Germany"],["dc.contributor.affiliation","Kaufmann, Martin; \r\n15\r\n2nd Department of Internal Medicine, Oncology and Hematology, Robert Bosch Hospital Stuttgart, Stuttgart, Germany"],["dc.contributor.affiliation","Dürholt, Mareike; \r\n16\r\nDepartment of Hematology/Oncology and Stem Cell Transplantation, Evangelisches Krankenhaus Essen-Werden, Essen, Germany"],["dc.contributor.affiliation","Hertenstein, Bernd; \r\n17\r\nDepartment of Hematology/Oncology, Klinikum Bremen-Mitte, Bremen, Germany"],["dc.contributor.affiliation","Klein, Stefan; \r\n18\r\nMedizinische Klinik III, Universitäts Medizin Mannheim, Mannheim, Germany"],["dc.contributor.affiliation","Ringhoffer, Mark; \r\n19\r\nMedizinische Klinik III, Städtisches Klinikum Karlsruhe, Karlsruhe, Germany"],["dc.contributor.affiliation","Mueller, Carlheinz R.; \r\n20\r\nZKRD - Zentrales Knochenmarkspender-Register für Deutschland, German National Bone Marrow Donor Registry, Ulm, Germany"],["dc.contributor.affiliation","Frank, Sandra; \r\n21\r\nDRST – German Registry for Stem Cell Transplantation, Ulm, Germany"],["dc.contributor.affiliation","Schrezenmeier, Hubert; \r\n1\r\nInstitute of Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service, Baden Wuerttemberg-Hessen, and University Hospital Ulm, Ulm, Germany"],["dc.contributor.affiliation","Fuerst, Daniel; \r\n1\r\nInstitute of Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service, Baden Wuerttemberg-Hessen, and University Hospital Ulm, Ulm, Germany"],["dc.contributor.affiliation","Mytilineos, Joannis; \r\n1\r\nInstitute of Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service, Baden Wuerttemberg-Hessen, and University Hospital Ulm, Ulm, Germany"],["dc.contributor.author","Mytilineos, Daphne"],["dc.contributor.author","Tsamadou, Chrysanthi"],["dc.contributor.author","Neuchel, Christine"],["dc.contributor.author","Platzbecker, Uwe"],["dc.contributor.author","Bunjes, Donald"],["dc.contributor.author","Schub, Natalie"],["dc.contributor.author","Wagner-Drouet, Eva"],["dc.contributor.author","Wulf, Gerald"],["dc.contributor.author","Kröger, Nicolaus"],["dc.contributor.author","Murawski, Niels"],["dc.contributor.author","Einsele, Hermann"],["dc.contributor.author","Schaefer-Eckart, Kerstin"],["dc.contributor.author","Freitag, Sebastian"],["dc.contributor.author","Casper, Jochen"],["dc.contributor.author","Kaufmann, Martin"],["dc.contributor.author","Dürholt, Mareike"],["dc.contributor.author","Hertenstein, Bernd"],["dc.contributor.author","Klein, Stefan"],["dc.contributor.author","Ringhoffer, Mark"],["dc.contributor.author","Mueller, Carlheinz R."],["dc.contributor.author","Frank, Sandra"],["dc.contributor.author","Schrezenmeier, Hubert"],["dc.contributor.author","Fuerst, Daniel"],["dc.contributor.author","Mytilineos, Joannis"],["dc.date.accessioned","2021-04-14T08:29:52Z"],["dc.date.available","2021-04-14T08:29:52Z"],["dc.date.issued","2021"],["dc.date.updated","2022-02-09T13:21:37Z"],["dc.description.abstract","T-cell epitope matching according to the TCE3 algorithm classifies HLA-DPB1 mismatches in permissive and non-permissive. This classification has been shown to be predictive for mortality and acute GvHD (aGvHD) events in large international cohorts. We retrospectively genotyped HLA-DPB1 in 3523 patients transplanted in Germany between 2000 and 2014 and in their unrelated donors using an Illumina amplicon-NGS based assay. Aim of the study was to evaluate DP-compatibility beyond the established TCE3 algorithm by assessing the combined effect of several DP-mismatch parameters on post-transplant outcome. We implemented an extended DP-mismatch assessment model where TCE3, DP allotype expression with respect to rs9277534, mismatch vector and number of mismatches were conjointly taken into consideration. In this model, non-permissive HLA-DPB1 mismatches showed significantly increased aGvHD risk if they were accompanied by two HLA-DPB1 mismatches in GvH direction (HR: 1.46) or one mismatched highly expressed patient allotype (HR: 1.53). As previously reported, non-permissive HLA-DPB1 mismatches associated with a significantly higher risk of aGvHD and non-relapse mortality (HR 1.36 and 1.21, respectively), which in turn translated into worse GvHD and relapse free survival (HR 1.13). Effects on GvL and GvHD appeared strongest in GvH-directed non-permissive mismatches. Our study results support the consideration of additional HLA-DPB1 mismatch parameters along with the established TCE3 matching algorithm for refinement of future donor selection. In particular, our findings suggest that DP non-permissiveness associated with two HLA-DPB1 mismatches or at least on highly expressed mismatched patient allotype should be avoided."],["dc.identifier.doi","10.3389/fimmu.2020.614976"],["dc.identifier.eissn","1664-3224"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/83012"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-399"],["dc.publisher","Frontiers Media S.A."],["dc.relation.eissn","1664-3224"],["dc.rights","http://creativecommons.org/licenses/by/4.0/"],["dc.rights.uri","http://creativecommons.org/licenses/by/4.0/"],["dc.title","The Human Leukocyte Antigen-DPB1 Degree of Compatibility Is Determined by Its Expression Level and Mismatch Permissiveness: A German Multicenter Analysis"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","e564"],["dc.bibliographiccitation.journal","Blood Cancer Journal"],["dc.bibliographiccitation.volume","7"],["dc.contributor.author","Jaramillo, S."],["dc.contributor.author","Benner, Axel"],["dc.contributor.author","Krauter, Juergen"],["dc.contributor.author","Martin, H."],["dc.contributor.author","Kindler, Thomas"],["dc.contributor.author","Bentz, Martin"],["dc.contributor.author","Salih, H. R."],["dc.contributor.author","Held, Gerhard"],["dc.contributor.author","Koehne, C-H"],["dc.contributor.author","Goetze, K."],["dc.contributor.author","Luebbert, Michael"],["dc.contributor.author","Kuendgen, A."],["dc.contributor.author","Brossart, Peter"],["dc.contributor.author","Wattad, Mohammed"],["dc.contributor.author","Salwender, Hans-Juergen"],["dc.contributor.author","Hertenstein, Bernd"],["dc.contributor.author","Nachbaur, D."],["dc.contributor.author","Wulf, Gerald"],["dc.contributor.author","Horst, H-A"],["dc.contributor.author","Kirchen, Heinz"],["dc.contributor.author","Fiedler, Walter"],["dc.contributor.author","Raghavachar, Aruna"],["dc.contributor.author","Russ, Gudrun"],["dc.contributor.author","Kremers, Stephan"],["dc.contributor.author","Koller, Elisabeth"],["dc.contributor.author","Rune, Gabriele M."],["dc.contributor.author","Heil, Gerhard"],["dc.contributor.author","Weber, Daniela"],["dc.contributor.author","Goehring, Gudrun"],["dc.contributor.author","Doehner, Konstanze"],["dc.contributor.author","Ganser, Arnold"],["dc.contributor.author","Doehner, Hartmut"],["dc.contributor.author","Schlenk, Richard F."],["dc.date.accessioned","2018-11-07T10:24:13Z"],["dc.date.available","2018-11-07T10:24:13Z"],["dc.date.issued","2017"],["dc.description.abstract","The aim of this cohort study was to compare a condensed schedule of consolidation therapy with high-dose cytarabine on days 1, 2 and 3 (HDAC-123) with the HDAC schedule given on days 1, 3 and 5 (HDAC-135) as well as to evaluate the prophylactic use of pegfilgrastim after chemotherapy in younger patients with acute myeloid leukemia in first complete remission. One hundred and seventy-six patients were treated with HDAC-135 and 392 patients with HDAC-123 with prophylactic pegfilgrastim at days 10 and 8, respectively, in the AMLSG 07-04 and the German AML Intergroup protocol. Time from start to chemotherapy until hematologic recovery with white blood cells > 1.0 G/l and neutrophils > 0.5 G/l was in median 4 days shorter in patients receiving HDAC-123 compared with HDAC-135 (P < 0.0001, each), and further reduced by 2 days (P < 0.0001) by pegfilgrastim. Rates of infections were reduced by HDAC-123 (P < 0.0001) and pegfilgrastim (P = 0.002). Days in hospital and platelet transfusions were significantly reduced by HDAC-123 compared with HDAC-135. Survival was neither affected by HDAC-123 versus HDAC-135 nor by pegfilgrastim. In conclusion, consolidation therapy with HDAC-123 leads to faster hematologic recovery and less infections, platelet transfusions as well as days in hospital without affecting survival."],["dc.identifier.doi","10.1038/bcj.2017.45"],["dc.identifier.isi","000402205200004"],["dc.identifier.pmid","28548643"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/14973"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/42614"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","PUB_WoS_Import"],["dc.publisher","Nature Publishing Group"],["dc.relation.issn","2044-5385"],["dc.rights","CC BY-NC-SA 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by-nc-sa/4.0"],["dc.title","Condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemia"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","562"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Leukemia"],["dc.bibliographiccitation.lastpage","569"],["dc.bibliographiccitation.volume","30"],["dc.contributor.author","Gratwohl, Alois"],["dc.contributor.author","Pfirrmann, M."],["dc.contributor.author","Zander, A."],["dc.contributor.author","Kroger, Nikolaus"],["dc.contributor.author","Beelen, D."],["dc.contributor.author","Novotny, J."],["dc.contributor.author","Nerl, C."],["dc.contributor.author","Scheid, Christof"],["dc.contributor.author","Spiekermann, Karsten"],["dc.contributor.author","Mayer, J."],["dc.contributor.author","Sayer, Herbert G."],["dc.contributor.author","Falge, C."],["dc.contributor.author","Bunjes, Donald W."],["dc.contributor.author","Doehner, Hartmut"],["dc.contributor.author","Ganser, Arnold"],["dc.contributor.author","Schmidt-Wolf, Ingo G. H."],["dc.contributor.author","Schwerdtfeger, Rainer"],["dc.contributor.author","Baurmann, H."],["dc.contributor.author","Kuse, R."],["dc.contributor.author","Schmitz, Norbert"],["dc.contributor.author","Wehmeier, A."],["dc.contributor.author","Fischer, J. Th"],["dc.contributor.author","Ho, A. D."],["dc.contributor.author","Wilhelm, M."],["dc.contributor.author","Goebeler, M-E"],["dc.contributor.author","Lindemann, Hans Walter"],["dc.contributor.author","Bormann, M."],["dc.contributor.author","Hertenstein, Bernd"],["dc.contributor.author","Schlimok, G."],["dc.contributor.author","Baerlocher, Gabriela M."],["dc.contributor.author","Aul, Carlo"],["dc.contributor.author","Pfreundschuh, Michael"],["dc.contributor.author","Fabian, Merle"],["dc.contributor.author","Staib, Peter"],["dc.contributor.author","Edinger, M."],["dc.contributor.author","Schatz, M."],["dc.contributor.author","Fauser, A. A."],["dc.contributor.author","Arnold, R."],["dc.contributor.author","Kindler, Thomas"],["dc.contributor.author","Wulf, Gerald"],["dc.contributor.author","Rosselet, A."],["dc.contributor.author","Hellmann, A."],["dc.contributor.author","Schaefer, Edith"],["dc.contributor.author","Pruemmer, O."],["dc.contributor.author","Schenk, Marina"],["dc.contributor.author","Hasford, Joerg"],["dc.contributor.author","Heimpel, H."],["dc.contributor.author","Hossfeld, D. K."],["dc.contributor.author","Kolb, H-J"],["dc.contributor.author","Buesche, Guntram"],["dc.contributor.author","Haferlach, Claudia"],["dc.contributor.author","Schnittger, S."],["dc.contributor.author","Mueller, M. C."],["dc.contributor.author","Reiter, Alfred"],["dc.contributor.author","Berger, Uta"],["dc.contributor.author","Saussele, Susanne"],["dc.contributor.author","Hochhaus, Andreas"],["dc.contributor.author","Hehlmann, Ruediger"],["dc.date.accessioned","2018-11-07T10:17:45Z"],["dc.date.available","2018-11-07T10:17:45Z"],["dc.date.issued","2016"],["dc.description.abstract","Tyrosine kinase inhibitors represent today's treatment of choice in chronic myeloid leukemia (CML). Allogeneic hematopoietic stem cell transplantation (HSCT) is regarded as salvage therapy. This prospective randomized CML-study IIIA recruited 669 patients with newly diagnosed CML between July 1997 and January 2004 from 143 centers. Of these, 427 patients were considered eligible for HSCT and were randomized by availability of a matched family donor between primary HSCT (group A; N = 166 patients) and best available drug treatment (group B; N = 261). Primary end point was long-term survival. Survival probabilities were not different between groups A and B (10-year survival: 0.76 (95% confidence interval (CI): 0.69-0.82) vs 0.69 (95% CI: 0.61-0.76)), but influenced by disease and transplant risk. Patients with a low transplant risk showed superior survival compared with patients with high( P < 0.001) and non-high-risk disease (P = 0.047) in group B; after entering blast crisis, survival was not different with or without HSCT. Significantly more patients in group A were in molecular remission (56% vs 39%; P = 0.005) and free of drug treatment (56% vs 6%; P < 0.001). Differences in symptoms and Karnofsky score were not significant. In the era of tyrosine kinase inhibitors, HSCT remains a valid option when both disease and transplant risk are considered."],["dc.identifier.doi","10.1038/leu.2015.281"],["dc.identifier.isi","000371688500006"],["dc.identifier.pmid","26464170"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/14048"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/41288"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Nature Publishing Group"],["dc.relation.issn","1476-5551"],["dc.relation.issn","0887-6924"],["dc.rights","CC BY-NC-SA 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by-nc-sa/4.0"],["dc.title","Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]